Wishing you all the joys of the season! 
Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030
Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 – Regional Analysis – By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Growing Strategic Partnerships to Develop Antibody Drug Conjugates Fuels the Middle East & Africa Antibody Drug Conjugates Market
Antibody-drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For instance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyos proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.
Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates.
Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBios lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.
Middle East & Africa Antibody Drug Conjugates Market Overview
The Middle East & Africa antibody drug conjugates market is segmented into UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa. Government initiatives to strengthen pharmaceutical development and rising cases of cancer is propelling the market in this region. The Government of Saudi Arabia contributes notably to pharmaceutical development, which is subsequently expected to propel the antibody drug conjugates market in the future. For instance, on June 18, 2023, the Public Investment Fund (PIF), Saudi Arabias global investment organization, launched Lifera, a commercial-scale contract development and manufacturing organization (CDMO). The CDMO will enable the growth of the local bio/pharmaceutical industry, strengthen national resilience, and support Saudi Arabias position as a global pharmaceutical manufacturing destination. Lifera will focus on manufacturing essential biopharmaceutical products, including insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules. The company will also create partnerships with leading local and international companies and attract targeted investments to grow local capacity and strengthen domestic manufacturing in this sector.
Furthermore, in June 2022, an antibody-drug combination called trastuzumab deruxtecan (T-DXd) slowed tumor growth in patients with advanced breast cancer. The clinical trial conducted on 557 advanced breast cancer patients showed that the antibody-drug combo helped prolong the life expectancy in patients. Thus, the abovementioned factors will propel the antibody drug conjugates market in future.
Middle East & Africa Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Antibody Drug Conjugates Market Segmentation
The Middle East & Africa antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.
Based on technology, the Middle East & Africa antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.
Based on application, the Middle East & Africa antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.
Based on distribution channel, the Middle East & Africa antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.
Based on country, the Middle East & Africa antibody drug conjugates market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa antibody drug conjugates market in 2022.
Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, and Astellas Pharma Inc are some of the leading companies operating in the Middle East & Africa antibody drug conjugates market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Middle East & Africa antibody drug conjugates market was valued at US$ 72.73 million in 2022 and is expected to reach US$ 201.29 million by 2030, registering a CAGR of 13.6% from 2022 to 2030. Escalating pipeline of ADCs and rising incidences of cancer are among the critical factors attributed to the Middle East & Africa antibody drug conjugates market expansion.
Various biopharmaceutical companies are developing ADCs owing to the rising interest in ADCs as promising cancer treatment. Companies such as ImmunoGen, Inc; NBE-Therapeutics, Seagen Inc; ADC Therapeutics; Merck KGaA; Sorrento Therapeutics, Inc; Mythic Therapeutics; Sutro Biopharma; Peak Bio; Regeneron Pharmaceuticals; Asana BioSciences; Sanofi; Navrogen, Inc; and OBI Pharma have ADCs in the different developmental phases. It is anticipated that the commercial launch of the ADCs developed will significantly enhance market size.
The companies have developed a broad list of promising ADCs in the different clinical stages and pipelines to be commercialized. The list of ADCs in the pipeline includes Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN-151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, Torpedo, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.
Companies have also shared pre-clinical data related to their respective products. For instance, in April 2023, Mythic Therapeutics announced preclinical data for its MYTX-011 (cMET-targeting ADC). The data published included the highlights of MYTX-011 intended to treat a broad range of cMET+ cancers. Likewise, at the Association for Cancer Research Annual Meeting in April 2023, Araris Biotech AG announced its preclinical data on anti-Nectin-4 and anti-HER2 ADCs. The two ADCs were developed using the company’s proprietary linker technology. The data demonstrated improved anti-tumor activity of anti-Nectin-4 and anti-HER2 ADCs compared to respective FDA-approved ADCs in head-to-head in-vivo studies. Thus, the rise in innovative ADCs will likely propel the market growth exponentially in the coming years.
On the contrary, high cost of ADCs development and commercialization hampers the growth Middle East & Africa antibody drug conjugates market.
Based on technology, the Middle East & Africa antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 67.5% share of the Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 49.12 million. It is projected to garner US$ 134.20 million by 2030 to expand at 13.4% CAGR during 2022-2030.
Based on application, the Middle East & Africa antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 54.6% share of the Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 39.73 million. It is projected to garner US$ 113.41 million by 2030 to expand at 14.0% CAGR during 2022-2030.
Based on distribution channel, the Middle East & Africa antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 62.4% share of Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 45.37 million. It is projected to garner US$ 129.21 million by 2030 to expand at 14.0% CAGR during 2022-2030.
Based on country, the Middle East & Africa antibody drug conjugates market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia held 37.8% share of Middle East & Africa antibody drug conjugates market in 2022, amassing US$ 27.49 million. It is projected to garner US$ 80.51 million by 2030 to expand at 14.4% CAGR during 2022-2030.
Key players operating in the Middle East & Africa antibody drug conjugates market are Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, and Astellas Pharma Inc, among others.
– In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
– In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing and commercialization to maximize the potential of disitamab vedotin.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Antibody Drug Conjugates Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
6. Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Technology
6.1 Overview
6.2 Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Antibody Drug Conjugates Market – Country Analysis
9.1 Middle East & Africa Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 Middle East & Africa Antibody Drug Conjugates Market Breakdown, by Key Countries – Revenue (2022) (US$ Million)
9.1.3 Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
9.1.3.1 Saudi Arabia
9.1.3.1.1 Overview
9.1.3.1.2 Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 Saudi Arabia: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 Saudi Arabia: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 Saudi Arabia: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 UAE
9.1.3.2.1 Overview
9.1.3.2.2 UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.3 UAE: Antibody Drug Conjugates Market, by Technology
9.1.3.2.4 UAE: Antibody Drug Conjugates Market, by Application
9.1.3.2.5 UAE: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 South Africa
9.1.3.3.1 Overview
9.1.3.3.2 South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 South Africa: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 South Africa: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 South Africa: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.4 Rest of Middle East & Africa
9.1.3.4.1 Overview
9.1.3.4.2 Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.3 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Technology
9.1.3.4.4 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Application
9.1.3.4.5 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies’ Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 5. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 6. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 7. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 8. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 9. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 10. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 11. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 12. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 13. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 14. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 15. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 16. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 17. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 18. Glossary of Terms, Antibody Drug Conjugates Market
LIST OF FIGURES
Figure 1. Middle East & Africa Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. Middle East & Africa Antibody Drug Conjugates Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Middle East & Africa Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
Figure 6. Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Middle East & Africa Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: Middle East & Africa Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Middle East & Africa Antibody Drug Conjugates, by Key Country – Revenue (2022) (US$ Million)
Figure 20. Middle East & Africa: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
Figure 21. Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
The List of Companies – Middle East & Africa Antibody Drug Conjugates Market
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.